Intellia Therapeutics' Crispr-based treatment for a rare swelling condition, hereditary angioedema, has successfully met its goals in a late-stage trial. The company's one-time treatment reduced attacks by 87% compared to a placebo, meeting the study's main goal. Six months after the treatment, 62% of patients were free from attacks and weren't using other therapies. This is a milestone in the field of gene editing and puts Intellia on track to seek approval from the U.S. Food and Drug Administration. The only FDA-approved Crispr medicine currently exists is from Vertex Pharmaceuticals. If approved, the treatment will compete with other chronic drugs for HAE.